Environmental lawyer and volunteer riverkeeper RFK jr continues to make waves in his current job as head of the US Health and Human Services Agency. This time, he’s going after psychiatry. MAHA Madness The controversial master falcon keeper who claims to have driven around New York with a dead bear in his car, announced at […]
The post More MAHA Mayhem? appeared first on Medical News Bulletin.
The FDA has approved IV ocrelizumab for treatment of relapsing-remitting MS in children and adolescents aged 10 years and older and weighing at least 55 pounds, according to Genentech.
Ocrelizumab (Ocrevus, Genentech) has previously been approved to treat adults with primary progressive MS, and relapsing forms, including active secondary progressive disease, clinically isolated syndrome and relapsing-remitting disease.
“This approval represents a landmark for children living with MS in the U.S. and their families, which can help close the longstanding gap in high-efficacy treatment
DENVER — Glaucoma and hypertension were both linked with worsened cognitive performance, according to a poster presentation at the Association of Vision and Research in Ophthalmology.
Jason Greenfield, MD, Alon Harris, MD, and Yash Lahoti spoke with Healio about their study, which was designed to look at some of the unknown risk factors for glaucoma.
“Only intraocular pressure is recognized as a treatable risk factor by the FDA,” Harris said. “However, it’s clear that from the plethora of studies that are around there are many different risk factors that play a role in the occurrence, incidence
The FDA has approved zenocutuzumab-zbco as the first drug for certain patients with a rare and aggressive bile duct cancer.
Zenocutuzumab-zbco (Bizengri, Partner Therapeutics) received approval for adults with advanced, metastatic or unresectable neuregulin 1 (NRG1) fusion-positive cholangiocarcinoma who experience disease progression during or after previous systemic therapy.
Zenocutuzumab-zbco is the seventh drug to receive approval under the National Priority Voucher (CNPV) pilot program.
“Patients with this ultra-rare type of cancer desperately need new treatment options,” FDA
In the operating room, the “5-second rule” apparently does not apply.
Researchers at Duke University Medical Center deliberately dropped polyethylene knee and hip liners on the operating room (OR) floor and quickly scooped them up to see how quickly contamination occurred. They found clinically important pathogens contaminated 34% of liners within moments of hitting the floor.
“The most surprising finding was how quickly contamination occurred,” researcher Bobby Glenn Warren, MPS, infectious disease scientist and molecular epidemiologist at Duke University School of Medicine, told Healio.
Published results showed patients who received a higher number of corticosteroid injections before total shoulder arthroplasty experienced a higher rate of postoperative complications.
“We should apply some caution to the use of corticosteroid injections in patients that we know have a higher likelihood to undergo shoulder replacement in the future,” Ron Gilat, MD, of Tel Aviv Sourasky University Medical Center, told Healio. “It is something for us to think about and to discuss with our patients before doing these injections, especially if these are recurrent injections.”
In this video, Monica Avila, MD, MPH, discusses results that showed letrozole alone was not noninferior to chemotherapy followed by letrozole for low-grade serous ovarian, fallopian tube or peritoneal carcinoma.
In the phase 3, NRG-GY019 noninferiority trial, presented at the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, patients with stage II to IV disease who underwent cytoreductive surgery received either letrozole (Femara, Novartis) alone or standard treatment with paclitaxel and carboplatin followed by maintenance letrozole.
“That was shocking for everybody,” Avila, a
NEW ORLEANS — The National Kidney Foundation Spring Clinical Meetings opened with presentations on the latest innovations and wins in the kidney care space.
“My goal was to really summarize some of the key wins [in the field],” Kirk Campbell, MD, NKF president, told Healio. “There’s some tangible success on the legislative and innovation front.”
In his address, Campbell highlighted key initiatives underway by the NKF and kidney care partners, including CKDintercept, which outlines goals to double the proportion of adults who are aware of their kidney disease conditions and receive recommended
DENVER — Myopia progressed more slowly across 2 years in children wearing Acuvue Abiliti 1-Day daily disposable contact lenses, according to data presented at ARVO 2026.
Chinese children who wore Abiliti 1-Day lenses (Johnson & Johnson Vision) had less axial elongation and a lower increase in myopia, on average, compared with a real-world control group, according to Alex Nixon, OD, principal research optometrist at Johnson & Johnson Vision, and colleagues.
To learn more about the lens’ effect, Nixon and colleagues conducted a single-arm, open-label study among 70 children
NEW ORLEANS — Mentoring from other patients may contribute to faster recovery time for patients undergoing hemodialysis, according to study data presented at the National Kidney Foundation Spring Clinical Meetings.
“Dialysis is a demanding treatment,” Tiffany Veinot, MLS, PhD, the Joan C. Durrance Collegiate Professor of Information at the University of Michigan School of Information, told Healio. “One of the big complaints is how much dialysis takes away from patients’ ability to do things they enjoy, spend time with family, pursue hobbies, go to work. This is important for their quality of